A serious adverse event is an AE that met at least 1 of the following criteria:

• fatal
• life threatening
• required in-patient hospitalization or prolongation of existing hospitalization
• resulted in persistent or significant disability/incapacity
• congenital anomaly/birth defect
• other medically important serious event.

The relationship of each AE to study treatment was assessed by the investigator.

The following AE grading scale was used:

Mild: Transient or mild discomfort; no limitation in activity; no medical intervention/therapy required Moderate: Mild to moderate limitation in activity-some assistance may be needed; no or minimal medical intervention/therapy required Severe: Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible Life-threatening: Extreme limitation in activity, significant assistance required, significant medical intervention/therapy required, hospitalization probable.

Participants who received at least 1 dose of etelcalcetide in the current study (20130213).

The percentage of participants who maintained plasma parathyroid hormone (PTH) levels within the Kidney Disease Improving Global Outcomes (KDIGO) recommended range of not less than 2x the upper limit of normal (ULN) and not greater than 9x the ULN at months 6, 12, and 18, with the ULN based on the reference range of the assay used at the individual clinical site.

Participants who received at least 1 dose of etelcalcetide in the current study (20130213) with available data at each time point.

Percentage of participants with serum phosphorus less than or equal to the upper limit of normal for the assay used.

Participants who received at least 1 dose of etelcalcetide in the current study (20130213) with available data at each time point.

The percentage of participants with serum corrected calcium (cCa) reported for cumulative time intervals from day 1 through months 6, 12, and 18, using the participant's lowest recorded corrected calcium value during the time interval.

If serum albumin was less than 4.0 g/dL, serum calcium was corrected according to the following formula:

cCa (mg/dL) = total calcium (mg/dL) + (4 - albumin [g/dL])*0.8. If serum albumin was > 4.0 g/dL no correction was made.

Participants who received at least 1 dose of etelcalcetide in the current study (20130213) with available data at the beginning of the time interval.

The Common Terminology Criteria for Adverse Events (CTCAE) grades for laboratory parameter values were defined based on the upper/lower limit of normal from the local laboratories contracted by the study centers.

Participants who received at least 1 dose of etelcalcetide in the current study (20130213).

The number of participants who were binding antibody positive post-baseline with a negative or no result at baseline (where baseline for participants previously treated with etelcalcetide is Day 1 of the first study in which they were exposed to etelcalcetide and for participants previously treated with cinacalcet is the ending time point for study 20120360).

Participants who received at least 1 dose of etelcalcetide in the current study with a post-baseline antibody result during this study